Table 1.
Demographic and clinical characteristics of participants included in clinical studies.
| HEATHER (n = 20)a | SPARTAC (n = 19)b | |
|---|---|---|
| Sex | ||
| • Male | 20 (100%) | 5 (26%) |
| Age | 33 (28–40.8) | 27 (22–40) |
| Country | ||
| • UK | 20 (100%) | 4 (21%) |
| • South Africa/Uganda | 0 | 13 (68%) |
| • Other | 0 | 2 (11%) |
| Time between estimated date of seroconversion and antiretroviral therapy (ART) initiation (days) | 41.5 (22.5–55.3) | 109 (76–124) |
| Time of sampling (weeks since ART initiation) | 52.5 (52.0–57.6) | 47.9 (47.6–48.0) |
| Baseline CD4 T cell count (cells/μL) | 514 (376–628) | 634 (535–764) |
| Baseline HIV RNA (log10 copies/mL) | 6.32 (4.55–6.76) | 4.32 (3.68–4.95) |
Demographic and clinical characteristics of participants included in clinical studies. Values given represent n (%) for categorical variables and median (interquartile range) for continuous variables.
aData from these individuals contribute to Figures 3A–E and 5A,C and Figures S5A–D, S6A, S9, and S10 in Supplementary Material.
bData from these individuals contribute to Figure 5 and Table S4 in Supplementary Material.